TARGETING OF DRUGS AND DRUG CARRIERS WITHIN THE CARDIOVASCULAR-SYSTEM

被引:36
作者
TORCHILIN, VP
机构
[1] Center for Imaging and Pharmaceutical Research, Massachusetts General Hospital-East, Charlestown, MA 02129, 149
关键词
DRUG TARGETING; CIRCULATION; LUNG; HEART; THROMBOSIS; ATHEROSCLEROSIS; MYOCARDIAL INFARCTION; LUNG CANCER; TARGETED THROMBOLYTIC THERAPY; TARGETED IMAGING; MONOCLONAL ANTIBODY; LIPOSOME;
D O I
10.1016/0169-409X(95)00042-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The targeting of pharmaceuticals within the cardiovascular system is reviewed. The delivery of both diagnostic and therapeutic agents is discussed with the use of different soluble and particulate carriers, including liposomes, microspheres, and cells. Targeting of pharmaceuticals to pathological areas of the vascular bed involves diagnostics and treatment of thromboses, atherosclerosis, and different malignancies, Special emphasis is put on the targeted diagnostics (visualization) of thromboses and targeted thrombolytic therapy. Antibody-mediated and magnetically driven delivery of thrombolytic enzymes is discussed. Targeting of atherosclerotic lesions with specific antibody-based diagnostic preparations is considered. The interaction of particulate carriers (liposomes) with endothelial cells is analyzed. Lung-targeted delivery can be performed via both respiratory and circulatory routes. A brief description of aerosolized preparations is presented. Drug and carrier targeting to lung-specific antigens is described with a special emphasis on lung malignancy targeting. Principal systems for drug targeting to compromised myocardium are reviewed, with a primary impact on those based on anti-cardiac myosin antibodies, Targeted visualization of myocardial infarction and myocarditis is discussed, Possible use of liposomes, immunoliposomes and long-circulating (immuno)liposomes for targeting of pharmaceuticals to the heart is also considered.
引用
收藏
页码:75 / 101
页数:27
相关论文
共 242 条
[1]  
AHMAD I, 1992, CANCER RES, V52, P4817
[2]  
AHMED T, 1990, RESPIRATORY DRUG DEL, P208
[3]   USE OF MAGNETIC EMULSION AS A NOVEL DRUG CARRIER FOR CHEMOTHERAPEUTIC-AGENTS [J].
AKIMOTO, M ;
MORIMOTO, Y .
BIOMATERIALS, 1983, 4 (01) :49-51
[4]  
[Anonymous], 1988, LIPOSOMES DRUG CARRI
[5]   THE EFFECT OF NON-IONIC SURFACTANT VESICLE (NIOSOME) ENTRAPMENT ON THE ABSORPTION AND DISTRIBUTION OF METHOTREXATE IN MICE [J].
AZMIN, MN ;
FLORENCE, AT ;
HANDJANIVILA, RM ;
STUART, JFB ;
VANLERBERGHE, G ;
WHITTAKER, JS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (04) :237-242
[6]  
BALDESCHWEILER JD, 1990, Patent No. 9012595
[7]  
BALLESTER M, 1994, MONOCLONAL ANTIBODIE, P79
[8]  
BANDO K, 1989, Patent No. 342620
[9]  
BARBA LM, 1984, J EXP MED, V158, P2141
[10]   USE OF MANNOSYLATED LIPOSOMES FOR INVIVO TARGETING OF A MACROPHAGE ACTIVATOR AND CONTROL OF ARTIFICIAL PULMONARY METASTASES [J].
BARRATT, GM ;
NOLIBE, D ;
YAPO, A ;
PETIT, JF ;
TENU, JP .
ANNALES DE L INSTITUT PASTEUR-IMMUNOLOGY, 1987, 138 (03) :437-450